A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma
Status:
Completed
Trial end date:
2013-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety profile, pharmacokinetics,
pharmacodynamics and maximum tolerated dose of RAF265 in patients with locally advanced and
metastatic melanoma.
Phase II portion of study (dose expansion) has been cancelled with Amendment 7 as of Dec
2011.